Key Takeaways

Elinzanetant, a new drug to treat moderate-to-severe hot flashes and night sweats, has received federal approval

The drug is a nonhormonal menopause treatment that works in the brain and appears to help reduce sleep disturbances

In clinical trials, 80% of patients saw a 50% drop in hot flash frequency after 26 weeks

MONDAY, Oct. 27, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has approved a new nonhormonal treatment to help women manage menopause symptoms such as hot flashes and night sweats.

Elinzanetant (Lynkuet), a once-daily pill, is expected to be available within weeks.

These uncomfortable symptoms affect up to 80% of women during menopause and can last a decade or more, significantly affecting quality of life and sleep, according to The

See Full Page